1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Multiple Myeloma Treatment Market
2.2. Global Multiple Myeloma Treatment Market, By Type, 2023 (US$ Million)
2.3. Global Multiple Myeloma Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Multiple Myeloma Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Multiple Myeloma Treatment Market Vendors
3.2. Strategies Adopted by Multiple Myeloma Treatment Market Vendors
3.3. Key Industry Strategies
4. Multiple Myeloma Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Multiple Myeloma Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Drugs Therapy
5.3.1.1. Monoclonal Antibodies
5.3.1.1.1. Daratumumab
5.3.1.1.2. Elotuzumab
5.3.1.2. Immunomodulatory Drugs
5.3.1.2.1. Lenalidomide
5.3.1.2.2. Pomalidomide
5.3.1.2.3. Thalidomide
5.3.1.3. Proteasome Inhibitors
5.3.1.3.1. Ixazomib
5.3.1.3.2. Bortezomib
5.3.1.3.3. Carfilzomib
5.3.1.4. Chemotherapy
5.3.1.4.1. Doxorubicin HCl liposome
5.3.1.4.2. Melphalan
5.3.1.4.3. Cyclophosphamide
5.3.1.5. Histone deacetylase inhibitor
5.3.1.5.1. Panobinostat
5.3.1.6. Corticosteroids
5.3.1.6.1. Dexamethasone
5.3.1.6.2. Prednisone
5.3.2. Stem Cell Transplantation
5.3.2.1. Allogenic Stem Cell Transplants
5.3.2.2. Autologous Stem Cell Transplants
5.3.3. Biophosphonates
5.3.4. Radiation Therapy
5.3.5. Surgical Therapy


6. North America Multiple Myeloma Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
6.3.Multiple Myeloma Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)

7. UK and European Union Multiple Myeloma Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.Multiple Myeloma Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)

8. Asia Pacific Multiple Myeloma Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.Multiple Myeloma Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)

9. Latin America Multiple Myeloma Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
9.3.Multiple Myeloma Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)

10. Middle East and Africa Multiple Myeloma Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
10.3.Multiple Myeloma Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Multiple Myeloma Treatment Market: By Type, 2022-2032, USD (Million)

11. Company Profile
11.1. Janssen Biotech, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bristol-Myers Squibb
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Novartis AG
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Millennium Pharmaceuticals
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Celgene Corporation
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Kesios Therapeutics Limited
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Amgen, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Genzyme Corporation
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Juno Therapeutics
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Abbvie, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Array BioPharma
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Karyopharm Therapeutics
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Sanofi S.A
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Takeda Pharmaceutical Industries Ltd.
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives